Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide

被引：20

作者：

Montefusco, Vittorio ^{[1
]}

Galli, Monica ^{[2
]}

Spina, Francesco ^{[1
]}

Stefanoni, Paola ^{[2
]}

Mussetti, Alberto ^{[1
]}

Perrone, Giulia ^{[1
]}

De Philippis, Chiara ^{[1
]}

Dalto, Serena ^{[1
]}

Maura, Francesco ^{[1
]}

Bonini, Chiara ^{[3
]}

Rezzonico, Francesca ^{[1
]}

Pennisi, Martina ^{[1
]}

Roncari, Luisa ^{[1
]}

Soldarini, Martina ^{[1
]}

Dodero, Anna ^{[1
]}

Farina, Lucia ^{[1
]}

Cocito, Federica ^{[4
]}

Caprioli, Chiara ^{[2
]}

Corradini, Paolo ^{[1
,5
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy

[2] Hosp Papa Giovanni XXIII, Bergamo, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Clin Lab, I-20133 Milan, Italy

[4] Hosp San Matteo, Pavia, Italy

[5] Univ Milan, Chair Hematol, Milan, Italy

来源：

LEUKEMIA & LYMPHOMA | 2014年 / 55卷 / 09期

关键词：

Multiple myeloma; lenalidomide; thalidomide; autoimmune diseases; CHRONIC LYMPHOCYTIC-LEUKEMIA; VERSUS-HOST-DISEASE; HEMOLYTIC-ANEMIA; PLUS DEXAMETHASONE; LYMPHOMA; CELLS;

D O I：

10.3109/10428194.2014.914203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide (Thal) (n = 474), the second group with lenalidomide (Len) (n = 140) and patients in the third group were first treated with Thal followed by Len (Thal-Len) (n = 94). Absolute risk of AD was 0.4% for patients treated with Thal, 4.3% for Len and 1.1% for Thal-Len. ADs manifested prevalently as autoimmune cytopenias (55%), although we observed one vasculitis, one optic neuritis, one Graves' disease and one polymyositis. ADs occurred preferentially in the first months of IMiD treatment. A previous autologous transplant was shown to be a significant risk factor. All ADs were managed with IMiD discontinuation and steroids, resolving in a few weeks, except for Graves' disease and polymyositis.

引用

页码：2032 / 2037

页数：6

共 22 条

[1] Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease [J].